Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Side effects account for most of the instances of failure of candidate drugs at late stages of development. These development failures contribute to the exorbitant cost of bringing new compounds to market: a single withdrawal can represent a loss of more than $1 billion. Many unwanted actions of drugs affect the heart, resulting in potentially proarrhythmic alteration of ion channel function. Because these can be fatal, potential electrophysiological cardiotoxicity is among the most stringent exclusion criteria in the licensing process.

Original publication

DOI

10.1038/clpt.2010.95

Type

Journal article

Journal

Clin Pharmacol Ther

Publication Date

07/2010

Volume

88

Pages

130 - 134

Keywords

Animals, Cardiovascular Agents, Computer Simulation, Drug Discovery, Electrophysiology, Heart, Humans, Models, Statistical, Systems Biology